Growth

RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity

RVAC Medicines, an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group, announced the completion of its series B financing, bringing the company’s total funds raised since its inception in June 2021 to US$140 million.

RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity Read More »